ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1559

Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated

Ali Shahzad1, Farheen Jafri2, Bisharah Rizvi2, Xiongce Zhao3, Meryl Waldman3 and Sarfaraz A. Hasni4, 1National Institute of Arthritis, Musculoskeletal and skin diseases, NIAMS/NIH, Bethesda, MD, 2R-Research, Hamilton, NJ, 3NIDDK/NIH, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cyclophosphamide, rituximab and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic lupus erythematosus (SLE) is often complicated by resistance or partial response to initial immunosuppressive regimen and flares after initial response.  Optimal management of these patients is unclear due to lack of scientific evidence.   There is limited data suggesting that the combination of cyclophosphamide (CYC) and rituximab (RTX) may have efficacy in recurrent and treatment resistant lupus. We present our experience with intravenous (IV) CYC plus RTX combination and its comparison to CYC only therapy.

Methods:

Data   from SLE patients who were treated with IV CYC monotherapy only or IV CYC and RTX combination from 2000-2013 was retrospectively reviewed.  Patient’s demographic information, SLE duration, SLE manifestations, co-morbidities, relevant labs, response to therapy and post-treatment infections were recorded every month for the first 6 post –treatment months and then every 3 months up to 60 months( if available) or until last data entry.  Patients with incomplete data or insufficient follow-up(less than 6 months post-treatment) were not included.  IV CYC monotherapy was given according to the  NIH standard protocol for the treatment of lupus nephritis.  IV CYC and RTX combination therapy regimen consisted of simultaneous administration of IV CYC and 2 doses of RTX 1000 mg given 15 days apart. Combination regimen was prescribed based on clinician’s discretion most commonly for recalcitrant  or recurrent flares of lupus nephritis(LN). Predetermined definitions (based on published literature) were used to record flares (renal vs. non-renal) and response (complete, partial or no response). Statistical analysis was done using SAS software (SAS Inc., Cary, NC). 

Results:

A total of 43 SLE pts. with adequate follow up were identified: 31 (72%) received CYC; 12 (28%) received CYC plus RTX. Indications for   combination treatment were partial response or recurrent LN (10/12), CNS lupus(1/12) and treatment resistant extra-renal SLE(1/12). Most (75%) patients treated with CYC and RTX combo were previously treated with IV CYC , most commonly for  lupus nephritis. There was no difference in overall survival between CYC only and CYC and RTX combo groups.  In patients receiving combo treatment, median duration of follow –up was 36 months (6-50 months) prior to combo treatment and 21 months (6-60 months) after receiving the combo treatment.   In the 12 patients who received CYC plus RTX,  number of flares before receiving CYC and RTX combo was significantly higher= 38(Renal flares=26; non-renal flares=12) as compared to after receiving combo=13(Renal=3; non-renal=10).  There was no significant increase in bacterial, viral or fungal infections after receiving combo therapy.

 Conclusion:

CYC and RTX combination regimen may have efficacy  in reducing renal and non-renal lupus flares .  This does not appear to be  associated with increased risk of infections.  Long term sequelae if any, of this regimen is not  known.  Our study has inherent limitations due to its retrospective nature  and small sample size.  Based on these preliminary results we are planning a clinical trial  studying the efficacy and tolerability of CYC/RTX combination  in patients with recurrent severe SLE.


Disclosure:

A. Shahzad,
None;

F. Jafri,
None;

B. Rizvi,
None;

X. Zhao,
None;

M. Waldman,
None;

S. A. Hasni,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cyclophosphamide-and-rituximab-combination-treatment-for-severe-systemic-lupus-erythematosus-is-effective-and-well-tolerated/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology